---
document_datetime: 2025-01-13 15:49:22
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pepaxti-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: pepaxti-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.6985286
conversion_datetime: 2025-12-31 01:45:21.4281
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Pepaxti

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                             |
|----------------------|------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0015              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 09/01/2025                          |                                             | SmPC, Labelling and PL           | To update SmPC section 5.2 to correct an error in the number of patients Pharmacokinetic properties, Renal impairment. In addition the MAH has taken the opportunity to make some editorial corrections in the annexes and correct some errors in the translations. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IA/0013/G           | This was an application for a group of variations. B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits   | 03/10/2024   | n/a        |             |                                                             |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------------------------------|
| PSUSA/11013 /202402 | Periodic Safety Update EU Single assessment - melphalan flufenamide                                                                                                                                                                                                                                                            | 05/09/2024   | n/a        |             | PRAC Recommendation - maintenance                           |
| PSUSA/11013 /202308 | Periodic Safety Update EU Single assessment - melphalan flufenamide                                                                                                                                                                                                                                                            | 07/03/2024   | n/a        |             | PRAC Recommendation - maintenance                           |
| IA/0011             | B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure                                                                                                                                                                                                                           | 29/02/2024   | n/a        |             |                                                             |
| IA/0010             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                     | 09/02/2024   | n/a        |             |                                                             |
| IB/0008             | C.I.6.b - Change(s) to therapeutic indication(s) - Deletion of a therapeutic indication                                                                                                                                                                                                                                        | 01/02/2024   | 01/03/2024 | SmPC and PL |                                                             |
| IB/0009             | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                         | 30/01/2024   | n/a        |             |                                                             |
| II/0002             | Extension of indication to include treatment of patients with Multiple Myeloma who have received at                                                                                                                                                                                                                            | 14/09/2023   | 14/12/2023 | SmPC, Annex | Please refer to Scientific Discussion 'Pepaxti-H-C-5681-II- |

<div style=\"page-break-after: always\"></div>

|                     | least two prior lines of therapies for PEPAXTI, based on final results from study OP-103 OCEAN; this is a randomized, open-label phase III study in patients with relapsed or refractory multiple myeloma following two to four lines of prior therapies and who were refractory to lenalidomide and the last line of therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.2 of the RMP has also been submitted. In addition, the MAH took the opportunity to implement editorial changes in the SmPC. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |            | II and PL              | 0002'                             |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IB/0006             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 12/12/2023 | n/a        |                        |                                   |
| IAIN/0007           | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 27/11/2023 | 01/03/2024 | SmPC, Labelling and PL |                                   |
| IB/0004             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 20/11/2023 | 01/03/2024 | SmPC                   |                                   |
| PSUSA/11013 /202302 | Periodic Safety Update EU Single assessment - melphalan flufenamide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 31/08/2023 | n/a        |                        | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IB/0001   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)   | 19/12/2022   | 14/12/2023   | SmPC   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------|